Evidence map›Paper›PMID 32639929›Full record

ArticleJCO oncology practice2020

Strategic Operational Redesign for Successfully Navigating Prior Authorization Barriers at a Large-Volume Proton Therapy Center.

Eric D Brooks, Matthew S Ning, Matthew B Palmer, G Brandon Gunn, Steven J Frank, Aashish K Shah

Abstract read
In one paragraph

Article in JCO oncology practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. The Impact of Pandemic-Driven Care Redesign on Hospital Efficiency.Risk management and healthcare policy · 2024
    Review
  5. Article
  6. Review
  7. Insurance Approval for Definitive Proton Therapy for Prostate Cancer.International journal of particle therapy · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Eric D BrooksDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-8274-0683
Matthew S NingDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-2932-5584
Matthew B PalmerLegion Healthcare Partners, Houston, TX.
G Brandon GunnDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-8197-0380
Steven J FrankDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Aashish K ShahHCA Healthcare Sarah Cannon, Nashville, TN.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

purposePrior authorization (PA) can be a resource-intensive barrier to oncologic care. To improve patient access and reduce delays at our large, academic proton therapy center, we implemented a novel payor-focused strategy to efficiently navigate the PA process while eliminating physician burden and reducing inappropriate denials.

methodsIn 2017, business operations were redesigned to better reflect the insurance process: (1) certified medical dosimetrists (CMDs), with their unique treatment expertise, replaced our historical PA team to function as an effective interface among physicians, patients, and payors; (2) a structured, tiered timeline was implemented to hold payors accountable to PA deadlines; and (3) our PA team provided administrative leadership with requisite insurance knowledge. PA outcomes were compared 6 months before and after the intervention.

resultsAfter implementation of this multifaceted strategy, the median time to successful appeal (after initial denial of coverage) decreased from 30 to 18 days (

conclusionIncorporating payor-focused strategies can improve patient access in a cost-effective manner while decreasing time and administrative burden associated with the PA process. These operational concepts can be adapted for other oncologic practice settings facing analogous PA-related obstacles.

Indexed as

Prior AuthorizationProton TherapyHumansMedical OncologyNeoplasmsPhysicians

Identifiers

PMID32639929
PMCPMC8189610

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.